Great catch! Gerald continues to build out his management team while building a world-class biotech company.
Does anyone really believe LymPro is not going to take the AD research world by storm? Not only for AD, but possibly CTE as well. When Dr. Robert Stern mentioned he was currently using LymPro in one of his CTE studies with 100 patients.
A lot of smart people here, but perhaps we are simply ignorant of the knowledge to fully understand the LymPro data as it is being presented to the researchers. That being said, I continue to trust our management team to delivery the goods and keep us informed as best they can along the way. A signed LymPro partner and expansion into CLIA labs will go a long way in resolving misunderstandings regarding the data presented to date.
An interesting point I noted in the conference discussions was that several times the "gold" standard in AD diagnoses was stated as clinical diagnosis from an experienced physician, not the AmyVid scan claimed by joboggi (he calls it Amvid). Perhaps that belief is a result of being out of the medical practice for 15 the last years. More likely it's a result of simply trying to degrade the LymPro test as much as possible. In the end, the marketplace will prove who is right and who is wrong. My bet is on the company, their advisors, and the painstaking science they are developing. Looking forward to updates from Gerald and Jason Napadano.
– The IRRELEPHANT –
Posting Irrelevant Nonsense on a Message Board Near You
Does anyone really believe LymPro is not going to take the AD research world by storm? Not only for AD, but possibly CTE as well. When Dr. Robert Stern mentioned he was currently using LymPro in one of his CTE studies with 100 patients.
A lot of smart people here, but perhaps we are simply ignorant of the knowledge to fully understand the LymPro data as it is being presented to the researchers. That being said, I continue to trust our management team to delivery the goods and keep us informed as best they can along the way. A signed LymPro partner and expansion into CLIA labs will go a long way in resolving misunderstandings regarding the data presented to date.
An interesting point I noted in the conference discussions was that several times the "gold" standard in AD diagnoses was stated as clinical diagnosis from an experienced physician, not the AmyVid scan claimed by joboggi (he calls it Amvid). Perhaps that belief is a result of being out of the medical practice for 15 the last years. More likely it's a result of simply trying to degrade the LymPro test as much as possible. In the end, the marketplace will prove who is right and who is wrong. My bet is on the company, their advisors, and the painstaking science they are developing. Looking forward to updates from Gerald and Jason Napadano.
– The IRRELEPHANT –
Posting Irrelevant Nonsense on a Message Board Near You
